Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: REGENERON PHARMACEUTICALS INC
Awarding agency: Department of Defense / Department of the Army
Funding agency: Department of Defense / Department of the Army
Period of performance: 2021-01-12 to 2022-07-31
Current total value of award: $5565000000
Description: PRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19):THE GOVERNMENT IS PURCHASING 2,650,000 DOSES OF THE EMERGENCY USE AUTHORIZATION (EUA) THERAPEUTIC